Tenaya Therapeutics, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Filed March 23, 2022. This is an annual report, not a standalone fourth-quarter report.
Business context
Tenaya is a preclinical-stage biotechnology company developing therapies aimed at underlying causes of heart disease. It reported no product revenue and had not begun clinical trials by year-end. Its pipeline spans gene therapy, cellular regeneration and precision medicine.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $54.4 million | $31.1 million |
| General and administrative expense | $18.4 million | $7.8 million |
| Total operating expenses | $72.8 million | $38.9 million |
| Net loss | $72.7 million | $38.4 million |
| Net cash used in operating activities | $60.8 million | $35.4 million |
At December 31, 2021, cash and cash equivalents were $38.1 million and marketable securities were $213.2 million; together, cash, cash equivalents and investments totaled $251.3 million. Current assets were $255.4 million and current liabilities were $21.8 million. Total liabilities were $35.7 million, including operating lease liabilities; the filing reports no borrowing debt in the presented balance sheet. The company stated that available funds were expected to support its operating plan for at least 12 months from the filing date, while noting that estimates depend on assumptions and additional funding will be needed to complete development and commercialization.
No operating margin is meaningful because the company had no product revenue. The 2021 net loss included a $141,000 unrealized loss on marketable securities in other comprehensive loss.
Material changes versus 2020
- Net loss increased $34.3 million, or 89%, as operating expenses rose 87%. R&D expense increased 75%, primarily from higher facility and laboratory costs, personnel, and external preclinical and research services. G&A expense increased 136%, including public-company and IPO-related professional costs.
- Tenaya completed its IPO in August 2021, issuing 13.8 million shares at $15 per share and receiving $188.5 million in net proceeds. It also received $20.0 million in net proceeds from a Series C preferred-stock issuance earlier in 2021. Preferred shares converted into common stock upon the IPO.
- Investing cash outflow rose to $238.6 million, largely reflecting $213.4 million of marketable-security purchases and $25.1 million of property and equipment purchases. Year-end cash and cash equivalents fell from $128.5 million to $38.1 million as funds were invested in securities and operations.
Outlook, risks and notable items
- Management expected to submit IND applications for TN-201, targeting MYBPC3-associated genetic hypertrophic cardiomyopathy, and TN-301, an HDAC6 inhibitor, in the second half of 2022. TN-401, for PKP2-associated genetic arrhythmogenic right ventricular cardiomyopathy, was expected to enter IND-enabling studies, with an IND submission planned for 2023. These are plans, not assured outcomes.
- Tenaya was constructing a cGMP manufacturing facility intended to support early clinical production and expected it to be operational in the first half of 2022. The filing cautions that the company had limited manufacturing experience and faced execution, regulatory and supply-chain risks.
- All candidates remained preclinical; preclinical results may not predict human safety or efficacy. Other key risks include the need for substantial additional capital, clinical and regulatory uncertainty, reliance on third parties, intellectual-property challenges, competition, and possible COVID-19-related disruption.
- The FDA granted orphan drug designation to TN-201. The company reported no material litigation. Its financial statements received an unqualified audit opinion; the auditor did not opine on internal control effectiveness.
Most important facts for investors to verify
- Whether TN-201 and TN-301 IND submissions and the TN-401 development timeline were achieved as planned.
- Current cash, investment balances, spending rate and updated financing runway versus the stated 12-month estimate.
- Progress, cost and operational readiness of the cGMP facility, including manufacturing capacity and clinical-supply plans.
- Whether subsequent clinical or regulatory findings support the preclinical claims and intended patient populations.
- Potential dilution, including equity awards and future financing needs, and any material developments in intellectual-property risks.